Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.
Neuschwander-Tetri BA, et al.
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
Lancet. 2015.
PMID: 25468160
Free PMC article.
Clinical Trial.
INTERPRETATION: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification. FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases, Intercept Pharmaceuticals....
INTERPRETATION: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and …